Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria's weakness can largely be attributed to the previous decade's outperformance, a slight acceleration in smoking rate decline, and the ongoing government crackdown on e-cigarettes.

Altria Is Extremely Cheap: A Look At The Underlying Issues And Math

AbbVie

Allergan

Brookfield Property REIT Inc. - Ordinary Shares - Class A

Brookfield Property Partners

My retirement portfolio goal is maximum safe long-term income, investing in quality companies bought at good to great prices, run by competent or excellent management teams I can trust.

Why I Have 28% Of My Retirement Portfolio Invested In These 3 High-Yield Blue Chips

The leading e-cig maker is under attack as illness, death, and faith in its ability to meet challenges grow.

Altria's $13 Billion Juul Investment Is Going Up in Smoke

Carnival

Centene

FedEx

Twenty-First Century Fox

UnitedHealth Group

According to GuruFocus’ list of 52-week lows, these guru stocks have reached their 52-week lows.

52-Week Company Lows (Sep 30)

Enterprise Products Partners

Imperial Brands PLC

Johnson & Johnson

The 24-hour news cycle means we're constantly inundated with scary headlines creating fear of an imminent market downturn.

The Best Dividend Stocks To Buy In October

Bristol-Myers

Nordstrom

Despite substantial share price declines, these brand-name dividend stocks aren't yield traps.

3 Beaten-Down Dividend Stocks You Can Trust

Altria has been a tremendous performer for a very long time.

Why Altria Is A Bad Investment For The Long Term

Altria is joining my list of scandal-affected stocks due to the vaping investigations targeting Juul Labs.

Altria Primed To Follow Pattern For Scandal Stocks

Gilead Sciences

Regeneron Pharmaceuticals

Gilead Sciences, Altria, Regeneron Pharmaceuticals and Carnival present buying opportunities

Stocks That Fell to 3-Year Lows in the Week of Sept. 27

Philip Morris

A once-promising union to take on global competition has been definitively stubbed out.

Philip Morris Ends Merger Talks With Altria as Juul Woes Mount

Philip Morris (PM) rose 5 percent on Wednesday, after it announced that merger talks with Altria (MO) had ended. However, our view is that the stock will fail, as the current market cycle matures.

Philip Morris Ends Merge Talks With Altria, Faces Murky Future

Altria (MO) scraps plans to merge with Philip Morris and announces leadership change for JUUL.

Altria Ends Merger Talks, Makes Changes in JUUL & 2019 View

British American Tobacco

Smoke from the US vaping crisis has blown across the Atlantic.

British tobacco group says the US vaping crackdown is hurting its business

An array of global forces are aligning against it.

Is the E-Cig Industry on the Verge of Collapse?

"It's a moral position. I'm not predicting" the stock goes to zero, says Josh Brown, CEO of Ritholtz Wealth Management.

Josh Brown: I hope tobacco giant Altria's stock 'goes to zero'

The chief executive of e-cigarette maker Juul stepped down on Wednesday as merger talks between its biggest investor Altria and Philip Morris collapsed in the face of a regulatory backlash against vaping that could reshape the industry.

Juul boss exits in vaping crisis as Philip Morris, Altria axe merger talks

The MO-PM merger talks have ended, the merger is off.

The Altria-Philip Morris Merger Is Off: Now What?

Altria Group Inc. (NYSE: MO) and Philip Morris International Inc. (NYSE: PM) saw their shares moving in opposite directions after the companies announced that their merger discussions have ended and that they will no longer be pursuing a merger.

Altria’s Plans Go Up in Smoke

Altria: Certain Wealth In Uncertain Times

The chief executive of e-cigarette maker Juul stepped down on Wednesday, with his company beset by a regulatory backlash against vaping, and merger talks between its biggest investor Altria and Philip Morris collapsed.

Juul boss exits in vaping crisis as Philip Morris, Altria end merger talks

This is a "pivotal moment" for the vaping industry, Altria CEO Howard Willard said in a speech Wednesday at the Global Tobacco & Nicotine Forum.

Altria CEO says vaping industry is at 'pivotal moment' as it fends off onslaught of public backlash

Tobacco giants Philip Morris International  and Altria Group  have scrapped merger talks as Altria-backed e-cigarette maker Juul Labs sank deeper into crisis and said it would suspend advertising in the United States.

Philip Morris and Altria ditch merger talks as Juul faces crisis

Philip Morris International has abandoned merger talks with Altria Group and will instead focus on the launch of its tobacco heating product iQOS in the United States, the company said on Wednesday. “After much deliberation, the companies have agreed to focus on launching iQOS in the US as part of their mutual interest to achieve.

Philip Morris, Altria call off merger talks

Philip Morris International  has scrapped merger talks with Altria Group  and will instead focus on the launch of its tobacco-heating product iQOS in the United States, the company said on Wednesday.

Philip Morris and Altria ditch merger talks amid vaping crackdown

The merger was called off as regulation around vaping in the U.S. ramps up.

News for Altria Stock (MO)